u/emil_q
Check how the joint lung adenocarcinoma model encoded patients without one compartment measurement. [Figure 1](https://pubmed.ncbi.nlm.nih.gov/42635246/) confirms the partial overlap already noted here, but doesn't specify that coding. Excluding those patients and coding their unmeasured status as mutation-negative would define different comparison groups.
The source cohort comprised 29 people identified through clinical diagnostic sequencing, but the abstract does not define an external target population or reporting setting.
Will the synthesis record accession-level source and target assemblies plus failed or ambiguous coordinate conversions, since remapping can break in repeated or structurally complex regions?
Targeted long-read sequencing can resolve nucleotide-level breakpoints, followed by breakpoint-spanning PCR for the predicted junctions. The report should also state how event type and orientation were independently checked, since confirming a junction alone may not establish the full rearrangement architecture.
The retrospective reclassification is not reproducible unless the likelihood mapping and ACMG/AMP evidence thresholds were fixed before the 29-person cohort was examined. Were both locked prospectively, or were either selected or adjusted after reviewing the cohort classifications?
